Laboratorios Rubió is a family-owned company founded in 1968 by Salvador and Pelayo Rubió. Its primary goal was to launch medicines in the Spanish market to cover the existing unmet medical need. To that aim, the initial strategy was to develop magistral formula in Rubió’s family drugstore based in Barcelona (Plaza Real).
A non-existing product in the Spanish market, Resincalcio (Calcium polystyrene sulfonate) for the treatment of hyperkalemia, was the first product launched by the company. Its great success set the trend of Laboratorios Rubió future business strategy focusing on niche markets.
The leit motive for successive product launches was to provide the medical community with products able to cover other unmet needs and also non-existing product based on specific demand of healthcare professionals.
Following the same criteria, and as consequence of international alliances, Laboratorios Rubió has increased its internal portfolio.
Laboratorios Rubió has been pioneer and innovative among the Spanish laboratories focusing on the following pharmacological therapies.
1969 RESINCALCIO/SODIO (Calcium/Sodium polystyrene sulfonate)
1971 RESINCOLESTIRAMINA (Cholestyramine)
1976 MIOCRIN (Sodium Aurothiomalate)
1977 CUPRIPEN (D-Penicillamine)
1981 RUBIFEN (Methylphenidate hydrochloride)
1982 DIFOSFEN (Etidronate disodium)
1983 HYDRAPRES (Hydralazine)
1984 FENITOINA RUBIÓ (Parenteral Phenytoin sodium)
1993 ROYEN (Calcium acetate )
2000 CYSTISTAT (Sodium hyaluronic acid for vesical instillations)
2002 JALOPLAST(Sodium hyaluronic acid, gel and cream)
2002 DOLQUINE (Hydroxychloroquine sulphate)
2002 GELCLAIR (Hyaluronic acid, oral gel)
2007 REUTENOX (Tenoxicam)
2010 actimTM PROM (Diagnostic Test)
2010 actimTM PARTUS (Diagnostic Test)
2012 PROfertil (Food Supplement)
2012 CICATRIDINA (Hyaluronic Acid, for vaginal and rectal mucosa)
2013 VWNG (Arteriovenous fistulas device)
2013 ELASTOLABO (perineal massage balm)
2013 RUBIÓ SUPPLEMENTS
Our drugs are well known by the medical community worldwide and are being prescribed with complete guarantee and satisfaction. Moreover, our main goal remains to continuously provide innovative drug which are essential for reduced groups of patients with special needs.